ResMed stock surging, more gains to come, Barron’s says

ResMed stock has been rallying-and the best move now is simply to hold on for more gains, Jacob Sonenshine writes in this week’s edition of Barron’s. ResMed’s data show GLP-1 patients are more likely to use its machines when they start to focus on their respiratory health. The company has also acquired small software firms that provide data to patients and doctors. These businesses generate a small portion of total revenue, but they enable patients to better understand the condition and limit their healthcare costs, the author says, adding that it should result in earnings and sales that continue to grow beyond Wall Street projections.